CR11011A - Compuestos activos biologicamente marcados con fluorobenzoilo 18f como agentes de diagnostico por imagenes asi como precursores de benzotriazol-1-iloxi-benzoilo, 2,5-dioxo-pirrolidin-1-iloxi benzoilo y trimetilamonio benzoilo - Google Patents

Compuestos activos biologicamente marcados con fluorobenzoilo 18f como agentes de diagnostico por imagenes asi como precursores de benzotriazol-1-iloxi-benzoilo, 2,5-dioxo-pirrolidin-1-iloxi benzoilo y trimetilamonio benzoilo

Info

Publication number
CR11011A
CR11011A CR11011A CR11011A CR11011A CR 11011 A CR11011 A CR 11011A CR 11011 A CR11011 A CR 11011A CR 11011 A CR11011 A CR 11011A CR 11011 A CR11011 A CR 11011A
Authority
CR
Costa Rica
Prior art keywords
iloxi
precursors
fluorobenzoil
benzoiloon
benzoilo
Prior art date
Application number
CR11011A
Other languages
English (en)
Inventor
Ananth Srinivasan
Timo Stellfeld
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07090035A external-priority patent/EP1964848A1/en
Priority claimed from EP07090079A external-priority patent/EP1985624A3/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CR11011A publication Critical patent/CR11011A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Zoology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nuclear Medicine (AREA)

Abstract

SE REFIERE A COMPUESTOS DE BENCENO SUSTITUIDOS MARCADOS RADIOACTIVAMENTE PARA DIAGNOSTICO POR IMAGINES. PROVEE METODOS PARA PREPARAR ESTOS COMPUESTOS, EN PARTICULAR, PARA PREPARAR NUEVOS COMPUESTOS QUE SIRVEN COMO PRECURSORES PARA LA MARCACION CON 18F, Y EL USO DE ESTOS COMPUESTOS MARCADOS CON 18F PARA DIAGNOSTICO POR IMAGINES. FORMULA (A), DONDE UNO DE -Y1, -Y2, -Y3, -Y4 E -Y5 ES -A-B-D-P, DONDE -A-B-D ES UN ENLACE O UN SEPARADOR, P ES UN PEPTIDO, UN PEPTIDOMIMETICO, UN OLIGONUCLEOTIDO O UNA MOLECULA PEQUENA. K ES LG-O O W, DONDE LG- SE SELECCIONA DEL GRUPO QUE COMPRENDE LA FORMULA (B), EN LA CUAL T ES H O CL, Q ES CH O N, K ESTA AUSENTE O ES C=O, W ES UN ISOTPO RADIOACTIVO DE FLUOR, CON MAYOR PREFERENCIA, 18F.
CR11011A 2007-03-01 2009-09-01 Compuestos activos biologicamente marcados con fluorobenzoilo 18f como agentes de diagnostico por imagenes asi como precursores de benzotriazol-1-iloxi-benzoilo, 2,5-dioxo-pirrolidin-1-iloxi benzoilo y trimetilamonio benzoilo CR11011A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07090035A EP1964848A1 (en) 2007-03-01 2007-03-01 Radiofluorination methods
EP07090079A EP1985624A3 (en) 2007-04-23 2007-04-23 Single step method of radiofluorination of biologically active compounds or biomolecules

Publications (1)

Publication Number Publication Date
CR11011A true CR11011A (es) 2009-10-19

Family

ID=39522200

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11011A CR11011A (es) 2007-03-01 2009-09-01 Compuestos activos biologicamente marcados con fluorobenzoilo 18f como agentes de diagnostico por imagenes asi como precursores de benzotriazol-1-iloxi-benzoilo, 2,5-dioxo-pirrolidin-1-iloxi benzoilo y trimetilamonio benzoilo

Country Status (22)

Country Link
US (1) US20090317326A1 (es)
EP (1) EP2146753A2 (es)
JP (1) JP2010520229A (es)
KR (1) KR20090119966A (es)
AR (1) AR062796A1 (es)
AU (1) AU2007348145A1 (es)
BR (1) BRPI0721424A2 (es)
CA (1) CA2679514A1 (es)
CL (1) CL2007002672A1 (es)
CO (1) CO6220836A2 (es)
CR (1) CR11011A (es)
DO (1) DOP2009000210A (es)
EA (1) EA200901142A1 (es)
EC (1) ECSP099610A (es)
IL (1) IL200034A0 (es)
MX (1) MX2009009291A (es)
PA (1) PA8747701A1 (es)
PE (1) PE20081355A1 (es)
SV (1) SV2009003364A (es)
TW (1) TW200836764A (es)
UY (1) UY30595A1 (es)
WO (1) WO2008104203A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
MX2010010314A (es) 2008-03-21 2011-04-12 Gen Hospital Corp Compuestos y composiciones para la deteccion y el tratamiento de la enfermedad de alzheimer y trastornos relacionados.
US20100129290A1 (en) * 2008-11-26 2010-05-27 I.S.T. Corporation Smart contrast agent and detection method for detecting transition metal ions
US20100227794A1 (en) * 2008-11-26 2010-09-09 I.S.T. Corporation Smart contrast agent and method for detecting transition metal ions and treating related disorders
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
KR101478140B1 (ko) * 2011-05-13 2014-12-31 (주)퓨쳐켐 １８ｆ-표지 ｐｅｔ 방사성의약품의 전구체 및 그 제조방법
CA2838198A1 (en) * 2011-06-09 2012-12-13 Ge Healthcare Limited Distillation device and method
EP2751087A1 (en) 2011-06-30 2014-07-09 Piramal Imaging SA Direct synthesis of 18f-fluoromethoxy compounds for pet imaging and the provision of new precursors for direct radiosynthesis of protected derivatives of o-([18f]fluoromethyl)tyrosine
EP2540710A1 (en) 2011-06-30 2013-01-02 Bayer Schering Pharma Aktiengesellschaft New precursors for direct radiosynthesis of protected derivatives of O-([18F]Fluoromethyl) tyrosine
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084555A (en) * 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
US5723578A (en) * 1987-09-24 1998-03-03 The Administrators Of Tulane Educational Fund Peptide analogs of bombesin
US6083915A (en) * 1991-05-10 2000-07-04 Biomeasure, Inc. Method for treating liver cancer
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6639076B1 (en) * 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
CA2375920A1 (en) * 1999-06-14 2000-12-21 Eli Lilly And Company Compounds
WO2002036173A2 (en) * 2000-11-03 2002-05-10 Bristol-Myers Squibb Pharma Company Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation
WO2002044144A2 (en) * 2000-11-30 2002-06-06 Advanced Research And Technology Institute, Inc. Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds
TWI311133B (en) * 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
EP1597270A2 (en) * 2003-02-20 2005-11-23 University of South Florida Peptidomimetic inhibitors of stat3 activity and their medical uses
GB0305704D0 (en) * 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
WO2005002293A2 (en) * 2003-06-25 2005-01-06 Vanderbilt University Cox-2-targeted imaging agents
GB0420344D0 (en) * 2004-09-14 2004-10-13 Amersham Plc Diagnostic compounds
EP1809339A2 (en) * 2004-10-07 2007-07-25 Koninklijke Philips Electronics N.V. Compounds, kits and methods for use in medical imaging
WO2006083424A2 (en) * 2004-12-28 2006-08-10 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
US8440841B2 (en) * 2005-01-17 2013-05-14 Universitätsklinikum Münster 5-pyrrolidinylsulfonyl isatin derivatives
EP2289564A3 (en) * 2006-09-08 2012-11-14 Piramal Imaging SA Derivatives of aniline as precursors for F18-labeling

Also Published As

Publication number Publication date
KR20090119966A (ko) 2009-11-23
WO2008104203A3 (en) 2009-02-05
WO2008104203A2 (en) 2008-09-04
ECSP099610A (es) 2009-10-30
US20090317326A1 (en) 2009-12-24
IL200034A0 (en) 2010-04-15
CO6220836A2 (es) 2010-11-19
UY30595A1 (es) 2008-09-30
BRPI0721424A2 (pt) 2014-03-25
JP2010520229A (ja) 2010-06-10
AU2007348145A1 (en) 2008-09-04
EP2146753A2 (en) 2010-01-27
AR062796A1 (es) 2008-12-03
SV2009003364A (es) 2010-01-27
TW200836764A (en) 2008-09-16
DOP2009000210A (es) 2010-08-31
EA200901142A1 (ru) 2010-04-30
CL2007002672A1 (es) 2008-09-12
MX2009009291A (es) 2009-12-14
CA2679514A1 (en) 2008-09-04
PA8747701A1 (es) 2009-08-26
PE20081355A1 (es) 2008-12-05

Similar Documents

Publication Publication Date Title
CR11011A (es) Compuestos activos biologicamente marcados con fluorobenzoilo 18f como agentes de diagnostico por imagenes asi como precursores de benzotriazol-1-iloxi-benzoilo, 2,5-dioxo-pirrolidin-1-iloxi benzoilo y trimetilamonio benzoilo
BRPI0513812B8 (pt) método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical
CR10694A (es) Compuestos antagonistas del receptor de glucagon, composiciones que contienen dichos compuestos y procedimientos de uso
CO6382142A2 (es) Combinación farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un anti-epileptico.
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
NZ740644A (en) Glucagon receptor agonists
BRPI0814811A2 (pt) Composto, agente, método, e composição de diagnóstico, uso de um composto, e, método de formação de imagem
CR11420A (es) Moduladores de gpr40 bifenilo sustituidos
BRPI0510487A (pt) agentes de contraste para estudo por imagens de perfusão do miocárdio
CL2009001605A1 (es) Uso de los compuestos derivados de piridinil-1h-indol-amina y un agente antipsicotico para el tratamiento de la esquizofrenia, anomalias de la glucorregulacion, diabetes mellitus tipo ii y potenciacion en la liberacion de insulina.
UY32037A (es) Daa-piridina
CL2008002708A1 (es) Compuestos derivados de azaciclilisoquinolinona e isoindolinona, antagonistas de histamina-3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuestos; y uso del compuesto para el tratamiento de un trastorno cognitivo,
ECSP11011294A (es) Compuestos de anillo fusionados y su uso
CL2009000964A1 (es) Compuestos derivados de 1-aril-2-imino-1,2-dihidropiridina-3-carboxamida, antagonista del receptor adrenergico alfa 1d, composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de enfermedades del tracto urinario inferior.
CL2009001012A1 (es) Un metodo para el tratamiento de una condicion dependiente de progesterona que comprende el uso de una composicion que comprende una antiprogestina 19-noresteroide que contiene un anillo fenilo sustituido con monometilamina en la posicion 11 beta del carbono 11.
SV2010003748A (es) Preg-4-en-21, 17-carbolactonas sustituidas en el anillo c, asi como preparados farmaceuticos que las contienen
MA31201B1 (fr) Compositions pharmaceutiques comprenant un agent calcilytique
CL2009000904A1 (es) Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
BR112012033773A2 (pt) composição de formulação agroquímica,e, método para usar uma composição de formulação agroquímica.
CO2017010151A2 (es) Material de implante compuesto
CL2008001477A1 (es) Composicion farmaceutica compuesta por la combinacion sinergica de un agente anticonvulsivante como gabapentina y un agente antiinflamatorio no esteroideo como meloxicam, los rangos de concentracion presentes para la gabapentina son 3 a 300 mg y de 0,1 a 30 mg para meloxicam; y uso para tratar el dolor neuropatico
CL2013000927A1 (es) Compuestos derivados de de 1,4-oxazepina, inhibidores de la recaptacion de monoaminas; un medicamento; y su uso preventivo o terapeutico para depresion, ansiedad, tdah, ansiedad, entre otros.
AR065864A1 (es) Compuesto de oxi-ciclohexil-piperidinil-dihidro-benzimidazol-2-ona composicion farmacetica que lo comprende su uso para la preparacion de un medicamento y compuestos intermediarios para su preparacion
CL2008001296A1 (es) Uso de un antagonista del receptor y5 del npy para el tratamiento de un trastorno relacionado con el hipercortisolismo en un sujeto tal como el estres.
CY1116283T1 (el) Δοσολογια μοναδας apadenoson